Dr. Myla Lai-Goldman, CancerGuide CEO
DURHAM, NC – CancerGuide Diagnostics, a company developing genome-based cancer tests and services, has inked a multi-year strategic collaboration and license agreement with Laboratory Corporation of America. The company also named the investors in its $10.5 million raise, which we reported January 28 (See: CancerGuide Diagnostics raises $10.5M).
The financing was co-led by Hatteras Venture Partners and Intersouth Partners. LabCorp also is participating in the financing as an equity investor.
LabCorp and CancerGuide will collaborate in the development and commercialization of CancerGuide’s molecular oncology assays.
“Cancer is an extremely complex disease that accounts for almost one out of every four deaths in the United States. There is a tremendous need for diagnostic tools to optimize the management of the disease and take full advantage of available therapeutic options,” said Myla Lai-Goldman, M.D., CancerGuide CEO.
Unique partnership model
“Through our unique partnership model, CancerGuide will provide companion diagnostic development services to pharmaceutical and biotechnology companies to maximize the efficiency and effectiveness of the market entry strategies.”
“CancerGuide’s high value testing services will provide anxiously-waiting oncologists, pathologists, and researchers with the information necessary to prescribe the right drug for the right patient – thereby saving lives while reducing the costs of care and drug development,” said Garheng Kong, M.D., general partner of Intersouth Partners.
“CancerGuide is a uniquely-positioned company, with the optimal management team and a formidable strategic partner,” stated Clay Thorp, General Partner of Hatteras.
The CancerGuide management team is led by two former colleagues from LabCorp who have worked together for 18 years, Dr. Lai-Goldman and Bill Haas. The company was founded in 2006.
Online: www.cancerguidedx.com
Join hundreds of Marketing Professionals and Internet Execs at Atlanta’s premier Digital event – Digital Summit 2012
www.digitalsummit.com
Related Stories:
- CancerGuide Diagnostics inks collaboration deal with Duke
- CancerGuide Diagnostics closes on $10.5M financing
- NC’s LabCorp acquiring Tandem Labs
- NC-based Lab Corp buying Monogram Biosciences for $155M
- New Hatteras $60 million fund closes
© 2010, TechJournal. All rights reserved.
Tags: Biotech, CancerGuide Diagnostics, funding
[...] CancerGuide Diagnostics inks deal with LabCorp, names investors [...]